TORONTO– Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on innovation and research on endogenous tryptamines (biomolecules acting as psychoneuroplastogens) for mental health disorders and beyond, officially opens its new clinical psychedelic research facility in the University Hospital Onofre Lopes, taking a major step for the development of the next generation of pharmaceuticals.
“With the opening of our new clinical psychedelic research facility, we continue to distinguish ourselves in the global psychedelic landscape, strengthening our pioneering position in three molecules and developing a new kind of contemporary approach for psychedelic treatments. The past year and a half has been very intense and focused in terms of clinical research and drug development. This fantastic new facility will play a key role in shaping the future of our proposed commercial clinical trials in the U.S.”, commented Alejandro Antalich, CEO of Biomind Labs.
“This new facility and a highly qualified team of scientists further strengthens Biomind’s goal to lead psychedelics to a new frontier of mental health treatment. The facility will conduct the first Phase II Clinical Trial using inhaled DMT for treatment-resistant depression under the new model of psychiatric intervention with DMT in conjunction with traditional psychological approaches”, said Dr. Dráulio Aráujo, Scientific and Clinical Advisor of Biomind Labs.
